Adenis, Antoine

Baey, Charlotte

Bennouna, Jaafar

Berille, Jocelyne

Celier, Patrice

Ducreux, Michel

Mornex, Françoise

Oberic, Lucie

Peiffert, Didier

Pignon, Jean-Pierre

Viret, Frédéric

Ychou, Marc

Radiation Oncology

English

PubMed

Lucie Oberic

Frédéric Viret

Charlotte Baey

Marc Ychou

Jaafar Bennouna

Antoine Adenis

Didier Peiffert

Françoise Mornex

Jean-Pierre Pignon

Patrice Celier

Jocelyne Berille

Michel Ducreux

Springer - Publisher Connector

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

Abstract
          
            Background
            To explore possible improvement in the treatment of locally advanced pancreatic carcinoma (LAPC) we performed a randomized, non-comparative phase II study evaluating docetaxel - plus either daily continuous 5 FU or weekly cisplatin concurrent to radiotherapy. We report here the results of the docetaxel plus 5 FU regimen stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued.
          
          
            Methods
            Forty (40) chemotherapy-naive patients with unresectable LAPC were randomly assigned (1:1) to either continuous fluorouracil (5-FU) 200 mg/m2/day (protracted IV) and docetaxel (DCT) 20 mg/m2/week or DCT 20 mg/m2 and cisplatin (CDDP) 20 mg/m2, plus concurrent radiotherapy for a period of 6 weeks. The radiation dose to the primary tumor was 54 Gy in 30 fractions. The trial's primary endpoint was the 6-month crude non-progression rate (NPR). Secondary endpoints were tolerance, objective response rate, and overall survival. Accrual was to be stopped if at 6 months more than 13 disease progressions were observed in 20 patients.
          
          
            Results
            Eighteen (18) progressions occurred at 6 months in the 5-FU-DCT arm. Six-month NPR was 10% (95%CI: 0-23). Six and 12-month survivals were 85% (95%CI: 64-95) and 40% (95%CI: 22-61); median overall survival was 10.1 months. Median progression-free survival was 4.3 months. We report the case of one patient who was amenable to surgery and has been in complete response (CR) for 5.5 years. Toxicities grade ≥ 3 were reported in 75% of patients; no treatment-related death occurred. Severe toxicities were mainly vomiting (35%), abdominal pain (10%) and fatigue (10%).
          
          
            Conclusions
            Combination of 5-FU, docetaxel and radiotherapy has inadequate efficacy in the treatment of LAPC despite good tolerance for the 5-FU-DCT regimen.
          
          
            Trial Registration
            ClinicalTrials.gov: NCT00112697
            
          </jats:sec

Crossref

A case report of un-resectable pancreas body carcinoma successfully treated by chemoradiotherapy. Gan to Kagaku Ryoho

A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy. Gan To Kagaku Ryoho

A: Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer.

Alberts SR: Gemcitabine, Cisplatin, and Radiotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol

Brountzos EN: Successful Pancreaticoduodenectomy with Immediate Vascular Reconstruction in a Patient with Cancer of the Pancreatic Head and Celiac Artery Stenosis. A Case Report.

Capocaccia R: Comparative cancer survival information

Clin Oncol

Cognetti F: Docetaxel in advanced gastric cancer: Review of the main clinical trials. Acta oncologica

Crane C: Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage

Docetaxel: a review of its pharmacology and clinical activity.

F: Survival in 1001 Patients with Carcinoma of the Pancreas. Ann of Surg

François E, Ychou M: Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res

In vivo enhancement of tumor radio response by Taxotere (TXT). Proc Annu Meet Am Soc Clin Oncol

Invasion and metastasis in pancreatic cancer. Molecular Cancer

JL: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg

JP: A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

Kochman ML: Long term survival after pancreatic resection for pancreatic adenocarcinoma.

LS: Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest

Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol

One sample multiple testing procedure for phase II trials. Biometrics

Radiation-sensitizing effects of taxotere.

S: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.

Survival Following Curative Resection for Pancreatic Ductal Adenocarcinoma. A Systematic Review of the Literature.

Talamonti MS: Neoadjuvant Therapy for Pancreatic Cancer: A Current Review. J Surg Oncol

Tempero MA: Cancer and leukemia group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.

Tomao S: Long-Term Survival in Metastatic Pancreatic Cancer. A Case Report and Review of the Literature.

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.

V: A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer. Ann Surg Oncol

Wanebo HJ: Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer:

Y: A case of locally advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy. Gan To Kagaku Ryoho

file:///data/core-remote/dit/data/Springer-OA/pdf/10b/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTc0OC03MTdYLTYtMTI0LnBkZg==.pdf

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Crossref

Springer - Publisher Connector